New drug takes aim at hard-to-treat neuroendocrine prostate cancer

NCT ID NCT07639086

Not yet recruiting Disease control Sponsor: Virginia Commonwealth University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests a drug called sacituzumab tirumotecan in people with neuroendocrine prostate cancer, a rare and aggressive form that has progressed after platinum-based chemotherapy. The drug is given by IV infusion three times per 42-day cycle. The study measures how many patients' tumors shrink or disappear, and how long they live without the cancer worsening.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Sacituzumab tirumotecan
What this could lead to: If effective, this drug could offer a new treatment option for a rare and aggressive form of prostate cancer that has stopped responding to chemotherapy.
What could go wrong: This is a small, early-phase trial with only 20 participants. The drug may not shrink tumors or improve survival, and side effects from the infusion are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE PROSTATE CANCER (NEPC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Disease Progression prostate cancer prostate neuroendocrine neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEUROENDOCRINE PROSTATE CANCER (NEPC) PROSTATE CANCER

Contacts and locations

Locations

Virginia Commonwealth University

Richmond, Virginia, 23298, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.